<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347008</url>
  </required_header>
  <id_info>
    <org_study_id>FAPESP 2011/00012-3</org_study_id>
    <nct_id>NCT01347008</nct_id>
  </id_info>
  <brief_title>Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis</brief_title>
  <official_title>Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early phases of systemic sclerosis is characterized by inflammatory and microvasculature
      alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance
      vasculogenesis. The purpose of this study is to evaluate the effect of sildenafil citrate on
      hand blood flow of patients with systemic sclerosis, using Laser Doppler Imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progressive microangiopathy and endothelial dysfunction are identified in early phases of
      systemic sclerosis. These alterations may result in progressive reduction of vessel lumen,
      decreased blood flow, and a state of chronic hypoxia resulting in digital ulcers, digital
      pitting, and, in more severe cases, gangrene and amputation of the extremities. Few studies
      aimed to evaluate the effects of Sildenafil on the microcirculatory blood flow in patients
      with Raynaud's phenomenon secondary to systemic sclerosis (SS). Moreover, no study has
      evaluated the effect of this drug on the number and function of endothelial progenitor cells
      in SS patients. The relatively new technique of laser Doppler imaging (LDI) allows an
      objective measurement of superficial cutaneous microvascular blood flow and constitutes a
      promising approach in the assessment of the digital microvascular vasoreactivity in response
      to cold stimulus or in response to treatment in SSc patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus</measure>
    <time_frame>8 weeks</time_frame>
    <description>Finger blood flow of the four medial fingers, measured by laser Doppler imaging and expressed in arbitrary perfusion units (p.u.).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) After Cold Stimulus.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Frequency of Raynaud's Phenomenon Attacks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Daily frequency of RP attacks as self registered in a 1-week diary. Any episode of pallor or cyanosis of the hand/fingers was considered as a RP attack, and patients were supposed to register the daily amount of such episodes on a 1-week diary, previously to the medical visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <condition>Scleroderma, Diffuse</condition>
  <condition>Scleroderma, Limited</condition>
  <condition>Raynaud Phenomenon</condition>
  <arm_group>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Sildenafil citrate, 50mg, b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil citrate</intervention_name>
    <description>Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <other_name>Sildenafil citrate, EMS Sigma Pharma, Ltd, Brazil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Sugar pill)</intervention_name>
    <description>Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systemic sclerosis according to the classification criteria of the American College of
             Rheumatology (1980) with no more than 4 years since diagnosis

          -  Early systemic sclerosis as defined by LeRoy and Medsger (2001)

          -  6 or more Raynaud's crisis per week

          -  Written informed consent provided by the subjects prior to initiating study procedures

        Exclusion Criteria:

          -  Smoking

          -  Peripheral or central vasculopathy other than Systemic sclerosis

          -  Uncontrolled Diabetes

          -  Liver disease

          -  Pregnant or lactating woman

          -  Current use of cyclosporin, prostanoids, bosentan or any PDE-5 inhibitors (including
             current Sildenafil use during randomization)

          -  History of stroke, myocardial infarction or life threatening cardiac condition within
             the last 6 months

          -  History of surgical sympathectomy

          -  Systolic blood pressure &lt; 85mm Hg

          -  History of scleroderma renal crisis

          -  Known hypersensitivity to Sildenafil or any of the excipients

          -  History of Retinitis Pigmentosa

          -  Current use of Nitrates
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando V Andrigueti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Systemic Sclerosis Outpatient Clinic, Hospital Sao Paulo, UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>August 20, 2016</results_first_submitted>
  <results_first_submitted_qc>October 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Fernando Villela Andrigueti</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sildenafil</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <keyword>Laser Doppler Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
    <mesh_term>Scleroderma, Limited</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited at the Outpatient Clinic of The Federal University of Sao Paulo, between August 2011 and November 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil Citrate</title>
          <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil Citrate</title>
          <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="10.9"/>
                    <measurement group_id="B2" value="41.6" spread="13.3"/>
                    <measurement group_id="B3" value="44.5" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digital skin microvascular blood flow measured by Laser Doppler Imaging (LDI) before cold stimulus</title>
          <description>Finger blood flow of the four medial fingers, measured by laser Doppler imaging and expressed in arbitrary perfusion units (p.u.).</description>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213.1" spread="87.9"/>
                    <measurement group_id="B2" value="241.9" spread="104.4"/>
                    <measurement group_id="B3" value="234.6" spread="105.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digital skin microvascular blood flow measured by Laser Doppler Imaging (LDI) after cold stimulus.</title>
          <description>Finger blood flow of the four medial fingers, measured by laser Doppler imaging and expressed in arbitrary perfusion units (p.u.). Measure taken after submersion of both hands in water at 15°C for 1 minute.</description>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.8" spread="92.4"/>
                    <measurement group_id="B2" value="218.6" spread="98.9"/>
                    <measurement group_id="B3" value="200.2" spread="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily frequency of Raynuad's Phenomenon attacks</title>
          <description>Daily frequency of RP attacks as self registered in a 1-week diary. Any episode of pallor or cyanosis of the hand/fingers was considered as a RP attack, and patients were supposed to register the daily amount of such episodes on a 1-week diary, previously to the medical visit.</description>
          <units>number of attacks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="2.5"/>
                    <measurement group_id="B2" value="1.9" spread="2.0"/>
                    <measurement group_id="B3" value="2.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus</title>
        <description>Finger blood flow of the four medial fingers, measured by laser Doppler imaging and expressed in arbitrary perfusion units (p.u.).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Citrate</title>
            <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus</title>
          <description>Finger blood flow of the four medial fingers, measured by laser Doppler imaging and expressed in arbitrary perfusion units (p.u.).</description>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.0" spread="108.0"/>
                    <measurement group_id="O2" value="246.3" spread="122.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) After Cold Stimulus.</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Citrate</title>
            <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) After Cold Stimulus.</title>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.7" spread="123.3"/>
                    <measurement group_id="O2" value="220.5" spread="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Frequency of Raynaud's Phenomenon Attacks</title>
        <description>Daily frequency of RP attacks as self registered in a 1-week diary. Any episode of pallor or cyanosis of the hand/fingers was considered as a RP attack, and patients were supposed to register the daily amount of such episodes on a 1-week diary, previously to the medical visit.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Citrate</title>
            <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Frequency of Raynaud's Phenomenon Attacks</title>
          <description>Daily frequency of RP attacks as self registered in a 1-week diary. Any episode of pallor or cyanosis of the hand/fingers was considered as a RP attack, and patients were supposed to register the daily amount of such episodes on a 1-week diary, previously to the medical visit.</description>
          <units>number of attacks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.4"/>
                    <measurement group_id="O2" value="1.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil Citrate</title>
          <description>Oral Sildenafil citrate, 50mg, b.i.d.
Sildenafil citrate: Oral sildenafil citratre, 50mg b.i.d., 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects analyzed; blood flow differences due to outside temperature variations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fernando Villela Andrigueti, MD</name_or_title>
      <organization>Federal University of Sao Paulo</organization>
      <phone>+55 11 55764239</phone>
      <email>fernando.andrigueti@usp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

